source
- FDA approves Revolution Medicines' Rasonque for metastatic pancreatic cancerRevolution Medicines received FDA approval for its oral RAS inhibitor daraxonrasib, branded as Rasonque, to treat patients with metastatic pancreatic adenocarcinoma who have already received prior…
- FDA approves Rasonque, first therapy targeting genetic cause of advanced pancreatic cancerThe U.S. Food and Drug Administration has granted approval to Rasonque, a drug from Revolution Medicines, for patients with advanced pancreatic cancer. The medicine, whose generic name is daraxonra…